# RetinAI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/retinai

- Industry: Healthcare IT
- Headquarters: Bern, Switzerland
- Website: www.retinai.com/
- Total disclosed funding: $10M
- Latest round: Series B (Oct 16, 2024)
- Investors on record: 6

## About

Founded in 2017 and based in Bern, Switzerland, by CEO Carlos Ciller, Sandro Zanet, and Stefanos Apostolopoulos, Ikerian AG, doing business as RetinAI operates as a healthcare technology company that develops products using technologies in machine learning and computer vision for eye care professionals and patients. The company provides software solutions that collect, organize, and analyze health data from the eyes. The company's products include RetinAI Discovery and OmniViewer. In October 2025, EssilorLuxottica, acquired Ikerian AG from b2venture, Eureka-Eurostars, Matterwave Ventures Management, Sanoptis AG, Topcon Healthcare, Verve Ventures, and Zürcher Kantonalbank. 
RetinAI’s discovery platform supports data collection, processing, and visualization, enabling the analysis of disease progression and treatment outcomes. The platform caters to clinics, hospitals, pharmaceutical companies, and researchers by offering modular and certified AI solutions that handle various data formats. RetinAI also focuses on global collaboration, facilitating data sharing and research across organizations. The company's products include Discovery® Unity, Discovery® for clinical studies, and Discovery® for clinics, which provide AI-driven insights and support for clinical workflows and patient management.

The firm generates revenue from charging for its disease evaluation apps, which cost 100 credits at EUR 5 each, 500 credits at EUR 3.5 each, 1,000 credits at EUR 2.75 each, and 2,000 credits at EUR 2.5 each.

October 2025, acquisition enables Ikerian AG (RetinAI) to accelerate global deployment of its AI-driven retinal imaging and clinical-decision solutions by leveraging EssilorLuxottica’s scale, distribution, and technology ecosystem.

## Funding rounds

- Series B, Oct 16, 2024, $7.8M — Zürcher Kantonalbank, Sanoptis AG, Verve Ventures, Topcon Healthcare
- Series A, May 2, 2024 — Zürcher Kantonalbank, Verve Ventures, Matterwave Ventures Management, Topcon Healthcare
- Series A, Jun 1, 2023 — Zürcher Kantonalbank, Verve Ventures, Matterwave Ventures Management
- Seed, Jun 11, 2019, $2.3M — b2venture, Verve Ventures

## Investors

- b2venture (https://capitalatlas.ai/funds/b2venture) — Seed
- Verve Ventures (https://capitalatlas.ai/funds/verve-ventures) — Seed, Series A, Series B
- Zürcher Kantonalbank — Series A, Series B
- Matterwave Ventures Management (https://capitalatlas.ai/funds/matterwave-ventures-management) — Series A
- Topcon Healthcare — Series A, Series B
- Sanoptis AG — Series B